PO.SHP01.01 · 科学与健康政策
扁桃体鳞状细胞癌患者生存的社会经济与临床预测因素
Socioeconomic and clinical predictors of survival in patients with squamous cell tonsillar cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:扁桃体癌是头颈部恶性肿瘤中一个独特且研究不足的亚组,其发病率不断上升,主要由人乳头瘤病毒(HPV)相关的口咽癌所驱动。理解临床特征和社会经济因素的作用,对于优化早期检测和改善该人群的结局至关重要。本研究旨在识别扁桃体癌患者中治疗延迟和总生存期(OS)的关键人口学、临床和社会经济预测因素。
方法:我们利用监测、流行病学和最终结果(SEER)数据库(2010-2021年)开展了一项基于人群的回顾性队列研究,纳入年龄20-85岁以上、患有原发性扁桃体癌的个体。数据使用SEER*Stat版本提取。主要终点为OS。采用多变量Cox比例风险回归以及经Shapley加性解释(SHAP)增强的机器学习模型来评估预后因素和模型可解释性。模型性能与随机生存森林(RSF)分析进行了比较。
结果:在6148名I-IV期扁桃体鳞状细胞癌患者中,随访期间发生1457例(23.7%)死亡(中位总生存期[OS]为46个月;四分位距[IQR]为18-85个月)。近半数(47.5%)就诊时为IV期疾病,且多数为男性(84.3%)。在治疗方面,2574名(42%)仅接受放化疗,而1381名(22.5%)接受放化疗联合手术。队列以非西班牙裔(NH)白人为主(81%),其次为西班牙裔(7.1%)、NH黑人(6.6%)和其他/未知(5.3%)。在校正后的Cox模型中,较差的生存独立地与以下因素相关:IV期(HR 2.21;95% CI 1.72-2.47)、肿瘤大小>40 mm(HR 2.09;95% CI 1.73-2.54)、较大年龄(HR 2.71;95% CI 2.22-3.31)、远处转移(HR 3.47;95% CI 2.78-4.32)、农村居住(HR 1.28;95% CI 1.10-1.50)、家庭收入低(HR 1.17;95% CI 1.04-1.33)以及NH黑人种族(HR 1.57;95% CI 1.33-1.88)。随机生存森林表现出良好的区分度(C指数0.715),与Cox模型(0.759)相当。SHAP分析识别出转移、分期、淋巴结受累、收入、农村程度以及种族/族裔为关键预测因素。
结论:在这项大型、基于人群的扁桃体鳞状细胞癌研究中,近半数患者就诊时已为晚期疾病,且社会经济劣势与较差的生存密切相关。机器学习分析识别出转移、疾病分期、淋巴结受累和社会因素为关键预测因素,提示将临床和社会背景整合到预后模型中或可指导有针对性的早期检测和精准生存策略,以减少不平等。
查看英文原文 English abstract
Background: Tonsillar cancer represents a distinct and understudied subset of head and neck malignancies with rising incidence, largely driven by human papillomavirus (HPV), associated oropharyngeal cancer. Understanding the roles of clinical characteristics and socioeconomic factors is critical for optimizing early detection and improving outcomes in this population. This study aimed to identify key demographic, clinical, and socioeconomic predictors of treatment delay and overall survival (OS) among patients with tonsillar cancer.
Methods: We conducted a population-based retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database (2010-2021), including individuals aged 20-85+ years with primary tonsil cancer. Data were extracted using SEER*Stat version. The primary endpoint was OS. Multivariable Cox proportional hazards regression and machine learning models enhanced with Shapley additive explanations (SHAP) were used to assess prognostic factors and model interpretability. Model performance was compared with random survival forest (RSF) analyses.
Results: Among 6,148 patients with Stage I-IV tonsillar squamous cell carcinoma, 1,457 (23.7%) deaths occurred during follow-up (median overall survival [OS], 46 months; interquartile range [IQR], 18-85 months). Nearly half (47.5%) presented with stage IV disease, and most were male (84.3%). Regarding treatment, 2,574 (42%) received chemoradiation alone, while 1,381 (22.5%) underwent combined chemoradiation and surgery. The cohort was predominantly non-Hispanic (NH) White (81%), followed by Hispanic (7.1%), NH Black (6.6%), and Other/Unknown (5.3%). In adjusted Cox models, poorer survival was independently associated with stage IV (HR, 2.21; 95% CI, 1.72-2.47), tumor size >40 mm (HR, 2.09; 95% CI, 1.73-2.54), older age (HR, 2.71; 95% CI, 2.22-3.31), distant metastases (HR, 3.47; 95% CI, 2.78-4.32), rural residence (HR, 1.28; 95% CI, 1.10-1.50), low household income (HR, 1.17; 95% CI, 1.04-1.33), and NH Black race (HR, 1.57; 95% CI, 1.33-1.88). The random survival forest demonstrated good discrimination (C-index 0.715), comparable to that of the Cox model (0.759). SHAP analysis identified metastasis, stage, nodal involvement, income, rurality, and race/ethnicity as key predictors.
Conclusion: In this large, population-based study of squamous cell carcinoma of the tonsil, nearly half of the patients presented with advanced disease, and socioeconomic disadvantage was strongly associated with poorer survival. Machine learning analysis identified metastasis, disease stage, nodal involvement, and social factors as key predictors, suggesting that integrating clinical and social context into prognostic models may guide targeted early detection and precision survivorship strategies to reduce disparities.
利益披露 Disclosure
S. Karanth, None..
P. Sandow, None..
M. Shinde, None..
K. Hitchcock, None..
C. Migliorati, None..
D. Braithwaite, None.